There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hookipa Pharma (HOOK – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with bullish sentiments.
Hookipa Pharma (HOOK)
JMP Securities analyst Roy Buchanan reiterated a Buy rating on Hookipa Pharma today and set a price target of $8.00. The company’s shares closed last Wednesday at $0.85, close to its 52-week low of $0.72.
According to TipRanks.com, Buchanan has 0 stars on 0-5 stars ranking scale with an average return of -28.2% and a 23.5% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Pardes Biosciences, and Arbutus Biopharma.
Hookipa Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
Arcutis Biotherapeutics (ARQT)
In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics, with a price target of $61.00. The company’s shares closed last Wednesday at $10.96.
According to TipRanks.com, Ear is a 4-star analyst with an average return of 8.8% and a 26.7% success rate. Ear covers the Healthcare sector, focusing on stocks such as Satsuma Pharmaceuticals, ACADIA Pharmaceuticals, and Revance Therapeutics.
Currently, the analyst consensus on Arcutis Biotherapeutics is a Strong Buy with an average price target of $51.80, a 361.7% upside from current levels. In a report issued on March 1, Morgan Stanley also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HOOK: